| Autor: |
Litwin SE; Division of Cardiology, Medical University of South Carolina Charleston, SC.; Division of Cardiology, Ralph H Johnson Veterans Affairs Medical Center Charleston, SC., Faaborg-Andersen CC; Department of Internal Medicine, Massachusetts General Hospital/Harvard Medical School Boston, MA., Tedford RJ; Division of Cardiology, Medical University of South Carolina Charleston, SC. |
| Abstrakt: |
Competing Interests: Disclosure: SEL has received consulting fees from Axon, Corvia, and Eli Lilly and honoraria from Dignity Health and Medscape; and is on an advisory board for Novo Nordisk. RJT has received consulting fees from Abbott, Acorai, Aria CV, Acceleron/Merck, Alleviant, Boston Scientific, Cytokinetics, Edwards Lifesciences, Endotronix, Gradient, Medtronic, Morphic Therapeutic, Restore Medical, and United Therapeutics Corporation; is on an advisory board for Restore Medical; and has stock options in Aria CV. CCFA has no conflicts of interest to declare. |
